Ascendis Pharma Director Replaces 9,160 Board Warrants

Summary of Transaction

On September 28, 2026, Ascendis Pharma A/S (NASDAQ: ASND) filed a Form 4 on behalf of Director Jean-Jacques Bienaimé detailing a warrant restructuring dated April 14, 2026:

1. Disposition (Code D): Cancellation of 9,160 warrants previously granted on June 10, 2025, with an exercise price of $172.35 and an expiration date of June 10, 2035.
2. Acquisition (Code A): Award of 9,160 replacement warrants with an exercise price of $249.84 and an expiration date of April 14, 2036.

Terms and Vesting

• Vesting Schedule: The new warrants vest 25% on April 14, 2027, and in 36 equal monthly installments thereafter.
• Context: As noted in Footnote 2, the reporting person agreed to cancel the earlier warrant grant and was issued a new warrant package in connection with his appointment to the board of directors.

Market Impact & Significance

This transaction constitutes a routine corporate governance and equity compensation adjustment associated with a board appointment rather than open-market buying or selling. As such, it carries Low trading significance for market participants.